Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

Income Statement

Follow revenue through to earnings.

Revenue

$39.55M

FY 2025 · Annual

-31.6% YoY

Operating Income

-$108.00M

FY 2025 · Annual

Net Income

-$122.93M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

SGMO Earnings Waterfall · TTM

NASDAQ:SGMO · Revenue to Net Income

Key Ratios

EPS$-0.38
Gross Margin100.0%
Net Margin-2133.4%
P/E Ratio-1.2
P/S Ratio109.2

Analysis

$34.6M of revenue converted into -$123.3M of net income for the selected period. Gross margin is 100.0% and net margin is -2133.4%, showing how much revenue survives after costs and taxes. EPS is $-0.38, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026

How much revenue does SGMO generate?

Sangamo Therapeutics, Inc. (SGMO) reported $39.55M of revenue in fiscal 2025.

Is SGMO profitable?

Sangamo Therapeutics, Inc. (SGMO) reported -$122.93M of net income, with a net margin of -310.8%.